Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. (Q37424784)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19325518%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

review article

1 reference

title

Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19325518%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

3

Ewa Lech-Maranda

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19325518%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1

Tadeusz Robak

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19325518%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Anna Korycka-Wolowiec

series ordinal

2

object named as

Anna Korycka

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19325518%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

4

Pawel Robak

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19325518%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

language of work or name

English

0 references

publication date

23 March 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19325518%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19325518%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19325518%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

page(s)

1183-1226

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19325518%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19325518%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

24 January 2020

copyright license

start time

23 March 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Nucleoside analogues in the treatment of haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Mechanism of action of purine analogues in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Current treatment options in hairy cell leukemia and hairy cell leukemia variant

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Nucleoside transporters in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Recent progress in the management of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Non-Hodgkin's lymphoma: the evolving role of purine analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Waldenström's macroglobulinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Treatment of T-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Novel purine nucleoside analogues for hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Nelarabine: efficacy in the treatment of clinical malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Nelarabine use in leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Transporter-mediated protection against thiopurine-induced hematopoietic toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Oral fludarabine therapy in chronic lymphocytic leukemia--increased convenience

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Cladribine (2-chlorodeoxyadenosine)

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Programmed cell death and adenine deoxynucleotide metabolism in human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

2-Chloro-2'-deoxyadenosine induces apoptosis through the Fas/Fas ligand pathway in human leukemia cell line MOLT-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Caspases: key players in programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Determination of 2-chloro-2'-deoxyadenosine in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Application of population pharmacokinetics to cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Older and new formulations of cladribine. Pharmacology and clinical efficacy in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

CD26 expression correlates with a reduced sensitivity to 2'-deoxycoformycin-induced growth inhibition and apoptosis in T-cell leukemia/lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Discovery and development of clofarabine: a nucleoside analogue for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

The structure of human deoxycytidine kinase in complex with clofarabine reveals key interactions for prodrug activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Mechanisms for T-cell selective cytotoxicity of arabinosylguanine

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Editorial comment on the manuscript entitled 'Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction'.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Clofarabine and nelarabine: two new purine nucleoside analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Synthesis of second-generation transition state analogues of human purine nucleoside phosphorylase

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Syntheses and bio-activities of the L-enantiomers of two potent transition state analogue inhibitors of purine nucleoside phosphorylases

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Structure of human PNP complexed with ligands.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Regulation of p53 function and stability by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2′-deoxyguanosine in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Extended follow-up of patients with hairy cell leukemia after treatment with cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Hairy-cell leukemia: induction of complete remission with pentostatin (2'-deoxycoformycin)

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Pentostatin in the treatment of hairy-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Fludarabine therapy in hairy cell leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Pentostatin (Nipent) in the treatment of chronic lymphocyte leukemia and hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

21 January 2018

Prolymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

21 January 2018

Prolymphocytic leukemias

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Human CD34+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Cladribine for untreated or early low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Low dose 2-CdA schedule activity in splenic marginal zone lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Infectious complications of purine analog therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Infectious and immunosuppressive complications of purine analog therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14031183

Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.

21 January 2018

1 reference

12 December 2020

Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research

1 reference

12 December 2020

Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

1 reference

12 December 2020

Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine

1 reference

12 December 2020

Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent

1 reference

12 December 2020

Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine

1 reference

12 December 2020

Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase

1 reference

12 December 2020

Prophylactic strategies to meet infectious complications in fludarabine-treated CLL.

1 reference

12 December 2020

Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma

1 reference

12 December 2020

Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin)

1 reference

12 December 2020

Long-term follow-up of patients with hairy cell leukaemia treated with pentostatin: lymphocyte subpopulations and residual bone marrow infiltration

1 reference

12 December 2020

Infectious complications after 2-chlorodeoxyadenosine therapy.

1 reference

12 December 2020

Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin

1 reference

12 December 2020

Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up

1 reference

12 December 2020

2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia

1 reference

12 December 2020

Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells.

1 reference

12 December 2020

Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia

1 reference

12 December 2020

Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells

1 reference

12 December 2020

Analysis of 2-chloro-2'-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solid-phase extraction

1 reference

12 December 2020

Liquid chromatographic study of acid stability of 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, 2-chloro-2'-deoxyadenosine and related analogues

1 reference

12 December 2020

Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response

1 reference

12 December 2020

Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia

1 reference

12 December 2020

Purine nucleoside analogs in indolent non-Hodgkin's lymphoma.

1 reference

12 December 2020

Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine.

1 reference

12 December 2020

Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma

1 reference

12 December 2020

Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study

1 reference

12 December 2020

Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine.

1 reference

12 December 2020

An enzymatic kinetic method for the determination of 2'-deoxycoformycin in biological fluids

1 reference

12 December 2020

Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia

1 reference

12 December 2020

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients

1 reference

12 December 2020

Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia

1 reference

12 December 2020

Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA)

1 reference

12 December 2020

Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes

1 reference

12 December 2020

A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems

1 reference

12 December 2020

Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine

1 reference

12 December 2020

A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia

1 reference

12 December 2020

Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma

1 reference

12 December 2020

Long-term follow-up of patients with hairy cell leukemia after cladribine treatment

1 reference

12 December 2020

Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia.

1 reference

12 December 2020

Human monocytoid leukemia cells are highly sensitive to apoptosis induced by 2'-deoxycoformycin and 2'-deoxyadenosine: association with dATP-dependent activation of caspase-3

1 reference

12 December 2020

Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features.

1 reference

12 December 2020

Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review).

1 reference

12 December 2020

The biochemical and clinical consequences of 2'-deoxycoformycin in refractory lymphoproliferative malignancy.

1 reference

12 December 2020

Infections in patients with chronic lymphocytic leukemia treated with fludarabine

1 reference

12 December 2020

Current treatment options in prolymphocytic leukemia.

1 reference

12 December 2020

On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration

1 reference

12 December 2020

Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy

1 reference

12 December 2020

Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias

1 reference

12 December 2020

Purine nucleoside phosphorylase inhibitors in T-cell malignancies

1 reference

12 December 2020

The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype

1 reference

12 December 2020

Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite

1 reference

12 December 2020

Purine nucleoside antimetabolites in development for the treatment of cancer.

1 reference

12 December 2020

Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria

1 reference

12 December 2020

On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans

1 reference

12 December 2020

Complete remission in T-cell prolymphocytic leukemia with 2-chlorodeoxyadenosine.

1 reference

12 December 2020

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

1 reference

12 December 2020

2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.

1 reference

12 December 2020

Transport and metabolism of 9-beta-D-arabinofuranosylguanine in a human T-lymphoblastoid cell line: nitrobenzylthioinosine-sensitive and -insensitive influx

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.

1 reference

12 December 2020

Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial.

1 reference

12 December 2020

Clinical pharmacology of deoxycoformycin

1 reference

12 December 2020

Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia

1 reference

12 December 2020

Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria.

1 reference

12 December 2020

Hairy cell leukemia: survival and relapse. Long-term follow-up of purine analog-based therapy and approach for relapsed disease

1 reference

12 December 2020

Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2'-deoxyadenosine

1 reference

12 December 2020

Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies

1 reference

12 December 2020

Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine

1 reference

12 December 2020

Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study

1 reference

12 December 2020

Effectiveness of fludarabine in end-stage prolymphocytic leukemia

1 reference

12 December 2020

2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia

1 reference

12 December 2020

The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin

1 reference

12 December 2020

Pentostatin in the treatment of advanced hairy cell leukemia

1 reference

12 December 2020

Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications

1 reference

12 December 2020

P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia

1 reference

12 December 2020

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

1 reference

12 December 2020

Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2- fluoro-beta-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro- beta-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro- beta-D-ribofuranosyl)adenine in CEM cells

1 reference

12 December 2020

Long term outcome of patients with hairy cell leukemia treated with pentostatin

1 reference

12 December 2020

2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma

1 reference

12 December 2020

Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (

1 reference

12 December 2020

Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells

1 reference

12 December 2020

Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)--2 h infusion for 5 days--as first-line treatment for advanced low grade non-Hodgkin's lymphoma

1 reference

12 December 2020

Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy

1 reference

12 December 2020

Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1).

1 reference

12 December 2020

10.3390/MOLECULES14031183

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19325518%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19325518%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

1 reference